HR 7877

The Shane DiGiovanna Act aims to improve access to wound care treatment for individuals with epidermolysis bullosa (EB) by establishing a federal demonstration program. This program would require states to include specific wound care supplies and medications – such as antihistamines and dressings – as covered benefits under Medicaid for those with EB. The goal is to test the effectiveness of mandatory coverage and gather data on its impact on healthcare costs and patient outcomes. A final report will be submitted to Congress outlining the program's results and recommendations.